NYSE American USD

BiomX Inc. (PHGE)

0.5400

-0.0237

(-4.20%)

At close: May 16 at 4:00:00 PM EDT

BiomX Inc (PHGE) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience

BiomX Inc (PHGE) reports promising Phase 2 trial results, secures significant funding, and outlines strategic regulatory plans amidst financial improvements.

GuruFocus.com 2 days ago

PHGE
-4.20%
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report topline results in Q1 2026 In April 2025, shareholders approved exercise of warrants issued in $12 million in financings announced in February 2025; funds expected to provide runway through topline Phase 2b results for BX004 trial The Company will host a conference call and webcast toda

GlobeNewswire 3 days ago

PHGE
-4.20%
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates. To participate in the conference call, please

GlobeNewswire 10 days ago

PHGE
-4.20%
BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

BiomX (PHGE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks 30 days ago

PHGE
-4.20%
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced that, as previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the Securities and Exchange Commission on March 25, 2025, the audit opinion contained a going concern qualification from t

GlobeNewswire last month

PHGE
-4.20%
BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than 40% by week 10Compared to placebo, BX211 also produced statistically significant1 improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline) (p=0.048), and in reducing the expansion of ulcer area (p=0

GlobeNewswire last month

PHGE
-4.20%
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

In February 2025, BiomX announced a series of financings with total gross proceeds of approximately $12 million to support completion of Phase 2b study of BX004; topline results anticipated in Q1 2026Topline Phase 2 results for BX211 in diabetic foot osteomyelitis (DFO) expected by end of March 2025Initiated exploration and analysis of real-world evidence in people with Cystic Fibrosis (CF) on the relationship between Pseudomonas aeruginosa reduction and clinical outcomes, ahead of expected regu

GlobeNewswire last month

PHGE
-4.20%
BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025. A press release reporting the results will be available in the Investors section of the Company’

GlobeNewswire last month

PHGE
-4.20%
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million

Proceeds to support advancement of BX004 program through Phase 2b study topline results in cystic fibrosis (CF) patients, anticipated in Q1 2026 Financing will also support analysis of real-world evidence in people with CF to explore the relationship between P. aeruginosa reduction and clinical outcomes NESS ZIONA, Israel, Feb. 26, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies t

GlobeNewswire 2 months ago

PHGE
-4.20%
BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards

NESS ZIONA, Israel, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it received written notification from the NYSE American LLC (“NYSE American”), dated December 10, 2024, stating that the Company has regained compliance with all NYSE American LLC continued listing standards. Specifically, the Company has res

GlobeNewswire 4 months ago

PHGE
-4.20%
BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025 BX004 Phase 2b study in Cystic Fibrosis (CF) is now expected to report topline results in H1 2026 following resolved manufacturing delays Company to host conference call and webcast today at 8:00AM ET NESS ZIONA, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel

GlobeNewswire 5 months ago

PHGE
-4.20%
BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, November 14, 2024, at 8:00 a.m. ET, to report third quarter 2024 financial results and provide business and program updates. To participate in the conference call,

GlobeNewswire 6 months ago

PHGE
-4.20%
BiomX announces mandatory unit separation

BiomX announces a mandatory separation of its units, which trade under the ticker symbol “PHGE.U”, each of which consists of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock. Each warrant entitles the holder to purchase one-half of a share of Common Stock at price of $115 per share. On or about October 25, 2024, the Units will be mandatorily separated and will no longer trade on the NYSE American. In the separation, Unit holders will receive the number of

TipRanks 6 months ago

PHGE
-4.20%

PHGE-UN

PHGEW
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces the Company will present further data from BiomX’s Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections. The findings will be presented in two sessions at the North American Cy

GlobeNewswire 7 months ago

PHGE
-4.20%

PHGE-UN

PHGEW
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces today that Jonathan Solomon, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 - 11, 2024 at the Lotte New York Palace Hotel. Presentat

GlobeNewswire 8 months ago

PHGE
-4.20%

PHGE-UN

PHGEW
BiomX to Present Positive Phase 1b/2a Clinical Trial Data for BX004 at the European Respiratory Society (ERS) Congress 2024

GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces the Company will present data from BiomX’s Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections. The findings will be presented as a poster at the European Respiratory Society

GlobeNewswire 8 months ago

PHGE
-4.20%

PHGE-UN

PHGEW
UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split

In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units following the reverse stock split GAITHERSBURG, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units following t

GlobeNewswire 8 months ago

PHGE
-4.20%

PHGE-UN

PHGEW
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates

BiomX anticipates reporting important results in 2025 for two clinical assets from the Company’s leading phage therapy pipeline Recent stockholder vote approves conversion of Series X Non-Voting Convertible Preferred Stock (issued upon merger with Adaptive Phage Therapeutics and concurrent financing) to BiomX’s common stock Company will host a conference call and webcast today at 8:00 am ET GAITHERSBURG, Md., Aug. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Com

GlobeNewswire 8 months ago

PHGE
-4.20%

PHGE-UN

PHGEW
BiomX Inc. Announces 1-for-10 Reverse Stock Split

GAITHERSBURG, Md., Aug. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it intends to effect a one-for-ten reverse split (the "Reverse Stock Split") of the Company’s common stock (the "Common Stock"). The Common Stock will continue to trade on the NYSE American under the existing symbol “PHGE” and will begin tradi

GlobeNewswire 8 months ago

PHGE
-4.20%

PHGE-UN

PHGEW
BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024

GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, August 15, 2024, at 8:00 a.m. ET, to report second quarter 2024 financial results and provide business and program updates. To participate in the conference call, pl

GlobeNewswire 9 months ago

PHGE
-4.20%

PHGE-UN

PHGEW

Performance Overview

Return	PHGE	S&P 500 (^GSPC)
YTD	-26.03%	+1.30%
1-Year	-83.64%	+12.48%
3-Year	-93.16%	+48.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BiomX Inc. (PHGE)

BiomX Inc (PHGE) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million

BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

BiomX announces mandatory unit separation

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference

BiomX to Present Positive Phase 1b/2a Clinical Trial Data for BX004 at the European Respiratory Society (ERS) Congress 2024

UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split

BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates

BiomX Inc. Announces 1-for-10 Reverse Stock Split

BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024

Performance Overview